--- title: "SCYNEXIS (SCYX) news: offering and Nasdaq notice" url: "https://aibio.space/companies/scynexis/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SCYX offering and Nasdaq notice news: SCYNEXIS sets up at-the-market program for up to $50,000,000 of stock with Cantor. SCYNEXIS, Inc." --- SCYX SCYNEXIS, Inc. NASDAQ · United States # SCYNEXIS (SCYX) news SCYX offering and Nasdaq notice news Mergers · 2026-03-31 ## [SCYNEXIS acquires Poxel's PXL-770 for $8,000,000 upfront and up to $188,000,000 in milestones](https://aibio.space/news/scynexis-acquires-poxels-pxl-770-8-000-000-upfront-up-188-000-000/) Under an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license. ## Latest SCYNEXIS news 1. 2025-06-26 Listings [SCYNEXIS gets Nasdaq minimum bid price notice, has until December 17, 2025 to comply](https://aibio.space/news/scynexis-gets-nasdaq-minimum-bid-price-notice-has-until-december-17/) SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market. 2. 2025-06-26 Listings [SCYNEXIS receives Nasdaq notice for stock below $1.00, has until December 17, 2025](https://aibio.space/news/scynexis-receives-nasdaq-notice-stock-below-1-00-has-until-december-17/) SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market. 3. 2024-11-06 Financings [SCYNEXIS sets up at-the-market program for up to $50,000,000 of stock with Cantor](https://aibio.space/news/scynexis-sets-up-market-program-up-50-000-000-stock-cantor/) SCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance. ## SCYNEXIS at a glance - **Ticker**: SCYX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $54.1 million ### Related companies - [Cingulate](https://aibio.space/companies/cingulate/) NASDAQ: CING - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) NASDAQ: EIKN - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Inovio Pharmaceuticals](https://aibio.space/companies/inovio-pharmaceuticals/) NASDAQ: INO - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) NASDAQ: ADIL - [EOM Pharmaceutical Holdings](https://aibio.space/companies/eom-pharmaceutical/) OTC: IMUC ### Also on NASDAQ - [Grace Therapeutics](https://aibio.space/companies/grace-therapeutics/) GRCE - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) ATYR - [QuidelOrtho](https://aibio.space/companies/quidelortho/) QDEL - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) ANIX - [Adlai Nortye Group](https://aibio.space/companies/adlai-nortye/) ANL ## What SCYNEXIS does SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with its lead program in difficult-to-treat and drug-resistant fungal infections. It is developing its proprietary fungerp platform of triterpenoid antifungal agents, which are structurally distinct glucan synthase inhibitors. Ibrexafungerp, the first representative of the class, was approved by the FDA as BREXAFEMME for vulvovaginal candidiasis and for reducing the incidence of recurrent vulvovaginal candidiasis, in 2021 and 2022 respectively. Ibrexafungerp was licensed to GSK in May 2023. The second-generation compound SCY-247 is being evaluated in clinical trials, and the company completed the single and multiple ascending dose portions of an ongoing Phase 1 study of oral SCY-247 in 88 healthy subjects. The FDA has granted SCY-247 Qualified Infectious Disease Product status and Fast Track designations for the oral formulation. Other compounds from the platform are in earlier stages of development. | Product or program | What it is | Stage | |---|---|---| | BREXAFEMME (ibrexafungerp) | Oral antifungal for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, licensed to GSK | approved by the FDA | | SCY-247 | Second-generation oral fungerp antifungal for drug-resistant fungal infections | in clinical trials; Phase 1 study ongoing | | Other fungerp platform compounds | Compounds from the proprietary fungerp platform targeting unmet needs | earlier stages of development | Summarised from the company's [10-K filed Mar 4, 2026](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/scyx-20251231.htm). ## SCYNEXIS annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$22.3 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | [$26.4 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | | Net income (loss) | [-$8.6 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | [-$21.3 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | | Cash from operations | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | [-$24.0 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | | Cash and equivalents | [$21.3 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000027/) | [$16.1 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | | Short-term investments | [$18.8 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000027/) | [$43.2 million](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.5 million, plus short-term investments of $43.6 million, $54.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about SCYNEXIS Has SCYNEXIS raised money recently? Our latest story on this, dated Nov 6, 2024: "SCYNEXIS sets up at-the-market program for up to $50,000,000 of stock with Cantor". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scynexis-sets-up-market-program-up-50-000-000-stock-cantor/). Has SCYNEXIS received a Nasdaq deficiency notice? Our latest story on this, dated Jun 26, 2025: "SCYNEXIS gets Nasdaq minimum bid price notice, has until December 17, 2025 to comply". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scynexis-gets-nasdaq-minimum-bid-price-notice-has-until-december-17/). What is the ticker symbol of SCYNEXIS? SCYNEXIS, Inc. trades under the ticker SCYX on NASDAQ. Where is SCYNEXIS listed? SCYNEXIS, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0L49. What is the SEC CIK of SCYNEXIS? The SEC Central Index Key (CIK) for SCYNEXIS, Inc. is 1178253. Its filings are on SEC EDGAR. How many shares does SCYNEXIS have outstanding? 9,949,609 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is SCYNEXIS listed under? Our directory records SCYNEXIS, Inc. under United States. What does SCYNEXIS do? Our directory classifies SCYNEXIS, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of SCYNEXIS? The ISIN recorded for SCYNEXIS, Inc. is US8112923094. Does aibio.space cover SCYNEXIS? aibio.space lists SCYNEXIS, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does SCYNEXIS develop? SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with its lead program in difficult-to-treat and drug-resistant fungal infections. It is developing its proprietary fungerp platform of triterpenoid antifungal agents, which are structurally distinct glucan synthase inhibitors. What is BREXAFEMME (ibrexafungerp) from SCYNEXIS? BREXAFEMME (ibrexafungerp): Oral antifungal for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, licensed to GSK Stage: approved by the FDA. What is SCY-247 from SCYNEXIS? SCY-247: Second-generation oral fungerp antifungal for drug-resistant fungal infections Stage: in clinical trials; Phase 1 study ongoing. Is SCYNEXIS profitable? SCYNEXIS, Inc. reported a net loss of $8.6 million for the fiscal year ended Dec 31, 2025, and used $5.3 million of cash in operations, per its annual report to the SEC. How much does SCYNEXIS spend on research and development? $22.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: SCYNEXIS Members talk about SCYNEXIS (SCYX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at SCYNEXIS, newest first. Each line links the filing it comes from. 1. 2026-09-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000031/scyx-ex99_1.htm) 2. 2026-06-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000021/scyx-20260625.htm) 3. 2026-05-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/scyx-20260528.htm) 4. 2026-05-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000014/scyx-20260519.htm) 5. 2026-04-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1178253/000114036126017112/ny20069828x2_def14a.htm) 6. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1178253/000114036126015376/ny20069828x1_pre14a.htm) 7. 2026-03-31 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/d118823dex991.htm) 8. 2026-03-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000119312526133259/d122408dex991.htm) 9. 2025-06-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1178253/000095017025090374/scyx-20250620.htm) 10. 2025-03-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1178253/000095017025038044/scyx-20241231.htm) 11. 2024-11-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1178253/000095017024122273/form_424b5_-_nov._6_2024.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SCYX on TradingView](https://www.tradingview.com/symbols/NASDAQ-SCYX/). ## SEC filings and registration - **SEC name**: Scynexis Inc - **CIK**: 1178253 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SCYX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548 - **Phone**: 201-884-5485 - **Shares outstanding**: 9,949,609 as of 2026-08-01 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000037/scyx-20260925.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000035/scyx-20260918.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000031/scyx-20260909.htm) filed 2026-09-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000027/scyx-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000021/scyx-20260625.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/scyx-20260528.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000014/scyx-20260519.htm) filed 2026-05-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1178253/000117825326000011/scyx-20260331.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178253), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details SCYNEXIS, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SCYX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: SCYNEXIS, Inc. - **Ticker**: SCYX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8112923094 - **Other listed symbols**: LSE:0L49 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SCYX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/scynexis/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SCYNEXIS (SCYX) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/scynexis/